Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

Objective To evaluate whether a disease activity guided strategy of dose reduction of two tumour necrosis factor (TNF) inhibitors, adalimumab or etanercept, is non-inferior in maintaining disease control in patients with rheumatoid arthritis compared with usual care. Design Randomised controlled, op...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMJ
Päätekijät: van Herwaarden, Noortje, van der Maas, Aatke, Minten, Michiel J M, van den Hoogen, Frank H J, Kievit, Wietske, van Vollenhoven, Ronald F, Bijlsma, Johannes W J, van den Bemt, Bart J F, den Broeder, Alfons A
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group Ltd. 2015
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4391970/
https://ncbi.nlm.nih.gov/pubmed/25858265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmj.h1389
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia